Moleculin Biotech, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Moleculin is a clinical-stage pharmaceutical company with no product revenue; it is developing drug candidates for hard-to-treat cancers and viruses. Financial amounts below are in U.S. dollars; statement amounts are in millions unless noted.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 / prior year-end |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $4.252 million | $5.687 million |
| General and administrative expense | $2.393 million | $2.637 million |
| Total operating expenses | $6.677 million | $8.354 million |
| Net loss | $4.970 million; $2.02 per share | $7.915 million; $4.13 per share |
| Cash used in operations | $6.717 million | $6.017 million |
| Cash and cash equivalents | $16.824 million | $23.550 million at Dec. 31, 2023 |
| Total assets / total liabilities | $30.845 million / $9.258 million | $38.217 million / $12.144 million at Dec. 31, 2023 |
- Operating expenses fell by $1.677 million year over year, primarily because of lower clinical-trial activity and lower regulatory and legal costs. Operating cash use nevertheless increased by $0.700 million, mainly due to timing of drug-production and clinical-trial payments.
- Net loss improved partly because the company recorded a $1.455 million gain from revaluing liability-classified warrants, versus a $0.039 million gain a year earlier. This is a fair-value item, not operating revenue. Interest income declined to $0.241 million from $0.392 million as cash balances fell.
- Working capital was approximately $13.549 million at March 31. The balance sheet includes a $3.400 million warrant liability and lease liabilities; the filing does not show conventional borrowings.
- No stock was sold for cash during the quarter. The company reported 2,311,536 common shares outstanding at May 1, 2024.
Business developments and outlook
- Annamycin is the company’s lead candidate, being studied in Phase 1B/2 trials for acute myeloid leukemia (AML) and soft-tissue sarcoma lung metastases. For AML trial MB-106, the company reported preliminary intent-to-treat results for 20 evaluable subjects: a 45% composite complete remission rate and 55% overall response rate. In the 10-subject second-line subgroup, the reported rates were 60% and 70%, respectively. Median remission duration for the nine composite complete remissions was approximately 4.9 months. These data are preliminary and subject to change.
- The company said it believes MB-106 supports a planned Phase 2 registration-directed study, MB-108. This is a stated development plan, not a guarantee of trial initiation or regulatory approval.
- The company reported that an independent cardio-oncology expert had reviewed data from 84 subjects across five trials as of April 1, 2024, with no cardiotoxicity signal identified to date. The observation is based on clinical data available so far and does not establish future safety.
- The filing describes additional pipeline activity: a Northwestern University investigator-initiated WP1066 glioblastoma study was expected to begin in the near term; the company was pursuing external funding for further WP1122 development.
- After quarter-end, the company reported receiving an EMA orphan-drug designation for Annamycin for AML and a U.S. patent issuance, with another patent expected. It also reported regaining Nasdaq’s minimum-bid-price compliance after a 1-for-15 reverse stock split effective March 22, 2024.
Funding, risks, and contingencies
- Going concern: Management says the $16.8 million cash balance is expected to fund planned operations into the fourth quarter of 2024, but not for at least one year from issuance of the financial statements. The filing states that these conditions raise substantial doubt about the company’s ability to continue as a going concern. Further financing or cost reductions will be needed; availability is not assured.
- The company had $19.8 million available under its Lincoln Park equity purchase agreement at March 31, but had not used it in Q1. The agreement was scheduled to terminate July 1, 2024; the company was discussing an extension. A separate offering restriction prevented use until after June 26, 2024.
- The company disclosed an ongoing SEC investigation following a 2022 subpoena concerning documents, including materials related to its COVID-19 drug candidate. It says it does not know the investigation’s specific nature and cannot predict its outcome. Related expenses were approximately $0.1 million in Q1 2024; a potential insurance recovery remained under review and was not recorded. The filing lists no legal proceedings under Part II, Item 1.
- Key risks include clinical and regulatory uncertainty, the need to raise capital, dependence on third-party manufacturers and research partners, intellectual-property and licensing obligations, and possible delays or cost overruns. The filing also added risks concerning indirect taxes and customs duties in international operations.
Important facts for investors to verify
- Whether the company secured financing or extended the Lincoln Park facility, and whether its cash runway remains consistent with the stated Q4 2024 expectation.
- Updated, independently reviewed MB-106 efficacy and remission-duration results, and the timing, design, funding, and regulatory path for planned MB-108.
- Whether the reported Annamycin cardiac-safety observations remain supported as more subjects are assessed.
- The status and potential outcome of the SEC investigation and the insurance claim for related expenses.
- The filing reports weighted-average basic and diluted shares of 2,466,174 for Q1, versus 2,311,536 shares outstanding at March 31; investors may wish to reconcile the period-average figure with the ending share count and the reverse split.